MapLight Therapeutics, Inc.

MPLT

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Baker Bros. Advisors OrbiMed Advisors Perceptive Advisors

Catalysts

No catalysts tracked.

Position Details

Baker Bros. AdvisorsNEWFeb 17, 2026

Shares: 364,705Value: $6.4M

## Signal Note: Baker Bros. Initiates Position in MapLight Therapeutics (MPLT) **Note: The reported position value of ~$6.4B appears to be a data error — likely reflecting an incorrect price or share count, as MPLT's entire market cap is a fraction of that figure.** The actual position of ~364,705 shares is more consistent with a modest, early-stage stake. Baker Bros. initiating any new position in a micro-cap is notable given their concentrated, high-conviction style and deep biotech diligence capabilities. MapLight's lead asset, ML-007, is a novel biased agonist targeting the 5-HT2A receptor pathway for neuropsychiatric indications, positioning it in the competitive but high-value psychedelic-adjacent/neuropsychiatry space. This entry likely reflects conviction ahead of upcoming clinical data catalysts from early-stage

OrbiMed AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

AAVXF3 funds IRON3 funds BCRX3 funds CTMX3 funds PRAX3 funds DYN3 funds EWTX3 funds CELC

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: OrbiMed Initiates MapLight Position OrbiMed's new $952K stake in MPLT signals conviction in the company's clinical pipeline, likely centered on ML402 for wet AMD, which entered Phase 2b dosing in 2H24. The entry by a top-tier healthcare allocator with deep clinical expertise suggests confidence in MapLight's retinal gene therapy platform, though the position size is modest relative to OrbiMed's typical checks, implying either a staged entry or selective thesis.